An open-label study was carried out in 2016 in the united kingdom to analyze the feasibility, safety and efficacy of psilocybin in treating individuals with unipolar treatment-resistant depression with promising effects; although the examine was small and concerned only twelve individuals, seven of Those people patients satisfied formal standards f